tirzepatide use in pregnancy Pre‐Pregnancy GLP‐1 Receptor Agonist or and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry‐Over Versus Post‐Discontinuation Metabolic Rebound a Multinational Federated Cohort Tirzepatide, Mounjaro, Period Changes and

The SURPASS-CVOT trial is studying tirzepatides effect on CV events compared with dulaglutide and is expected to be completed in 2024

Another study showed that the drug reduced symptoms for people with heart failure

Researchers should watch for specific warning signs

Other factors that need to be taken into account when considering medication management are coverage and cost, other health conditions, and contraindications

This understanding has led to the development of GLP-1 receptor agonists (such as semaglutide and liraglutide) and dual GIP/GLP-1 receptor agonists (such as tirzepatide) as pharmaceutical treatments